Tag: ICRA
Indian hospital industry to add over 7,400 beds by FY2026: ICRA
ICRA forecasts a 12-14% revenue growth for Indian hospitals in FY2025, driven by capacity expansion and strong demand
Credit profile of Indian pharma companies to remain healthy in FY2025:...
Revenue growth to moderate to 8-10% in FY2025, post a healthy 13-14% YoY expansion in FY2024
Private hospital players expected to invest Rs 32,500 crore for adding...
Operating profit margin for ICRA’s sample set companies to remain healthy at over 22% in FY2024 supported by operating leverage and continued benefits from cost optimization measures
Indian hospital industry to remain strong in 2024, predicts ICRA
ICRA expects occupancy of its sample set to remain flattish at 64-65% in FY2024, while the ARPOB is expected to expand by 8-9%
Indian hospital industry in the pink of health: ICRA
Operating profit margin will remain healthy at over 22% in FY2024, supported by operating leverage and continued benefits from cost optimization measures
Majority of pharma industry to grow at 7-9% in FY2024: ICRA
USFDA inspections have gained momentum in the recent past and regulatory risks remain a key monitorable
Indian hospital industry to post robust performance in FY2023: ICRA
Aggregate occupancy for the sample set is estimated at 62-64% for FY2023. With ARPOB growth expected at 8-10% on a YoY basis, translating to 15-17% revenue growth
Pricing pressures & regulatory overhang affect margins of Indian pharma companies...
Continued pricing pressures in the US and European markets and cost inflation likely to result in 50-100 bps contraction in operating profit margin for ICRA’s sample set in FY2023
Outlook for the Indian pharma industry remains stable: ICRA
Continued pricing pressures in the US and European markets and cost inflation likely to result in 120-150 bps contraction in operating profit margin for ICRA sample set in FY2023
Revenue growth of hospitals to be moderate in FY2023: ICRA study
Aggregate occupancy for the sample set to be ~60-62% in FY2023; on a YoY basis, given the high base of FY2022, this translates to revenue growth of over 12%